BRCA2 pathogenic variants

About

Biomarker type: Germline variant

Gene context: BRCA2

Chromosome: 13

Requires pathogenic: True

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (2) HC (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) HC (2) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) HC (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone